- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Product quality issues.
Displaying page 1 of 1.
| EudraCT Number: 2016-004129-18 | Sponsor Protocol Number: AK581 | Start Date*: 2017-03-17 | ||||||||||||||||
| Sponsor Name:Akari Therapeutics Plc | ||||||||||||||||||
| Full Title: CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | ||||||||||||||||||
| Medical condition: Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) LT (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2017-000435-13 | Sponsor Protocol Number: JWGKDVAAP0117 | Start Date*: 2017-11-13 |
| Sponsor Name:University Hospital Frankfurt for its Dermatology Department, Clinical Research | ||
| Full Title: Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatmen... | ||
| Medical condition: Hidradenitis suppurativa is defined as a chronic inflammatory disease of the intertriginous area, including the axilla, groin and anogenital or submammary regions. The condition is characterized by... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-003256-32 | Sponsor Protocol Number: MO42245 | Start Date*: 2021-04-14 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: AN INTERVENTIONAL OPEN-LABEL MULTICENTER PHASE IV STUDY TO EVALUATE THE IMPACT OF EMICIZUMAB ON HEALTH-RELATED QUALITY OF LIFE, PHYSICAL ACTIVITY, AND JOINT HEALTH IN PATIENTS WITH SEVERE HEMOPHILI... | |||||||||||||
| Medical condition: Severe hemophilia A without factor VIII inhibitors | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
| Trial protocol: SE (Completed) NO (Completed) FI (Completed) DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002204-27 | Sponsor Protocol Number: GS030_CLIN_001 | Start Date*: 2017-12-22 |
| Sponsor Name:GENSIGHT-BIOLOGICS | ||
| Full Title: A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa | ||
| Medical condition: Retinitis Pigmentosa | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-003879-42 | Sponsor Protocol Number: 2021/ABM/03/00006 | Start Date*: 2023-04-12 | ||||||||||||||||
| Sponsor Name:Medical Univeristy of Bialystok | ||||||||||||||||||
| Full Title: A randomized, controlled, double-blind clinical trial evaluating the effect of METformin treatment on endometrial function in women diagnosed with Idiopathic Infertility | ||||||||||||||||||
| Medical condition: Potential causes of idiopathic infertility include in particular: abnormal function of the endometrium, including implantation disorders and immunological abnormalities, genetic abnormalities and t... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Female | |||||||||||||||||
| Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2014-000694-39 | Sponsor Protocol Number: SPL7013-018 | Start Date*: 2014-10-22 | |||||||||||
| Sponsor Name:Starpharma Pty Ltd | |||||||||||||
| Full Title: A phase 3, double-blind, multicentre, randomised, placebo-controlled study to determine the efficacy and safety of SPL7013 Gel (VivaGel®) to prevent the recurrence of bacterial vaginosis | |||||||||||||
| Medical condition: recurrent bacterial vaginosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: CZ (Completed) GB (Completed) HU (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-001449-15 | Sponsor Protocol Number: R668-AD-1225 | Start Date*: 2013-12-05 | |||||||||||
| Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
| Full Title: AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS | |||||||||||||
| Medical condition: Atopic dermatits | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) DE (Completed) PL (Completed) SE (Completed) LT (Completed) EE (Completed) DK (Completed) FI (Completed) ES (Completed) IT (Completed) NL (Completed) AT (Completed) BE (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003471-30 | Sponsor Protocol Number: D-FR-52120-222 | Start Date*: 2016-09-26 | |||||||||||
| Sponsor Name:Ipsen Innovation | |||||||||||||
| Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT... | |||||||||||||
| Medical condition: Urinary incontinence (UI) caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: RO (Completed) PT (Completed) CZ (Completed) IT (Completed) NL (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003281-27 | Sponsor Protocol Number: BCX7353-204 | Start Date*: 2017-12-27 | |||||||||||
| Sponsor Name:BioCryst Pharmaceuticals Inc | |||||||||||||
| Full Title: An Open-Label study to Evaluate the Long-Term Safety of Daily Oral BCX7353 in subjects with Type I and II Hereditary Angioedema | |||||||||||||
| Medical condition: Hereditary Angioedema | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) DK (Completed) AT (Completed) ES (Completed) SK (Completed) PL (Completed) BE (Completed) NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000507-44 | Sponsor Protocol Number: D-FR-52120-223 | Start Date*: 2016-06-29 | |||||||||||
| Sponsor Name:Ipsen Innovation | |||||||||||||
| Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT... | |||||||||||||
| Medical condition: Urinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed) LT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001056-17 | Sponsor Protocol Number: 3606 | Start Date*: 2020-08-14 | ||||||||||||||||
| Sponsor Name:Kings's College London [...] | ||||||||||||||||||
| Full Title: A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia. | ||||||||||||||||||
| Medical condition: Clinically significant agitation in Alzheimer's Diseases | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2017-001982-26 | Sponsor Protocol Number: OZM-063 | Start Date*: 2018-04-26 | |||||||||||
| Sponsor Name:The Hospital for Sick Children | |||||||||||||
| Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma... | |||||||||||||
| Medical condition: Unresectable or progressive low grade glioma | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.